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Summary Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the
induction of cytokine release and expansion of tumour-specific lymphocyte populations. In phase studies, tumour responses have been
observed in patients with malignant melanoma, lymphoma and ovarian carcinoma. The dose-limiting toxicity is myalgia. Sixteen patients (age
35-76 years, median 57 years) with malignant melanoma were treated. All had received prior chemotherapy. In each cycle of treatment,
patients received bryostatin 25 gg m-2 weekly for three courses followed by a rest week. The drug was given in PET diluent (10 gg bryostatin
ml- of 60% polyethylene glycol, 30% ethanol, 10°h Tween 80) and infused in normal saline over 1 h. The principal toxicities were myalgia
(grade 2, eight patients and grade 3. six patients) and grade 2 phlebitis (four patients), fatigue (three patients) and vomiting (one patient). Of
15 patients evaluable for tumour response, 14 developed progressive disease. One patient developed stable disease for 9 months after
bryostatin treatment. In conclusion, single-agent bryostatin appears ineffective in the treatment of metastatic melanoma in patients previously
treated with chemotherapy. It should. however, be investigated further in previously untreated patients.
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Protein kinase C (PKC) isoenzymes constitute a multicene familv
with several biochemical forms that are membrane associated and
phosphory late other downstream proteins (Nishizuka. 1986). PKC
isoenzymes are important components of signal transduction in
response to growth factors. hormones and tumour-promoting
phorbol esters. and are a common pathway in the regulation ofcell
growth by oncoproteins. PKC lexels may be altered in tumour
cells (Guillem et al. 1987: O'Brian and Ward. 1989: Barr et al.
1991: Couldwell et al. 1991). and cultured fibroblasts induced to
o-erexpress PKC by transfection with PKC cDNA exhibit a trans-
formed phenotype (Housey et al. 1988). Thus. PKC represents a
rational target for anti-cancer drug development to block a
common pathwax ofoncogene activation.
Brvostatin I is a novel anti-cancer dmua derixed from the marine
inxvertebrate Bugula neriina (Pettit et al. 1981 ). It is the prototype of
a novel class of structural1v related macrocvclic lactones w-hich
interact with PKC to affect cellular growth and differentiation.
cytokine secretion and stimulation of imnmunocompetent and
haemopoietic cells (Berkow and Kraft 1985: Fields et al. 1988:
Tuttle et al. 1992: Steube and Drexler. 1995). Brvostatins interact
with PKC through the phorbol ester bindincg site. binding with high
affinitx and a slow rate of release. Brvostatins induce some of the
responses of phorbol esters and antagonize those responses to
phorbol esters that they themselves do not induce (Dell'Aquila et al.
1988: Gschwendt et al. 1988: Kennedy et al. 1992: Lewin et al.
1992). The nature ofthe response to brvostatin is probably a function
of the target cell population and PKC isoenzymes. Some isoforms
are affected similarly by brvostatin and phorbol esters. and some
Received 30 January 1998
Revised 20 Apnl 1998
Accepted29April 1998
Correspondence to: AL Hams
differentially (Hocevar and Fields. 1991: Hocexar et al. 1992:
Kennedy et al. 1992: Lewin et al. 1992: Szallasi et al. 1994a.
1994b .
In Xivo. brx-ostatin has anti-tumour activity against B16
melanoma. M5076 oxarian reticulum cell sarcoma. P388 acute
leukaemia and L1OA B-cell lymphoma (Pettit et al. 1982:
Schuchter et al. 1991: Homung et al. 1992). In addition. brxostatin
has immunostimulator- properties that may contnrbute to its in
vivo anti-tumour activitx-. It stimulates cytokine release. enhances
T- and B-cell actixation and lxmphokine-acti-ated killer (LAK)
cell activitv as well as neutrophil phagocytic actix ity and degranu-
lation (Berkow and Kraft. 1985: May et al. 1987: Mohr et al. 1987:
Drexler et al. 1990: Esa et al. 1990: Tuttle et al. 1992: Scheid et al.
1994: Steube and Drexler. 1995).
Three phase I clinical trials of bryostatin hax-e been conducted
(Philip et al. 1993: Prendix-ille et al. 1993: Jayson et al. 1995). In
the first. brvostatin was administered as a 1 infusion in 60% ethanol
evenr 2 weeks for three cycles (Prendiville et al. 1993). Nineteen
patients received brvostatin at doses ranging between 5 and 65 .cg
m-'. The dose-limiting toxicity w-as myalgia. and the maximum
tolerated dose (MTD) was 35 jg m-'. At 65 jgc m-'. but not at lower
doses. there was sinnificant haematological toxicitv. The second
trial. undertaken by the same centre. used brn ostatin infused in PET
diluent (10 go brvostatin mlr- of 60% polyethylene glycol. 30%-
ethanol. 10% Tween 80) and infused with nonnal sahine oxer 24 h
everv week for 8 weeks (Jayson et al. 1995). The MTD w-as
25 jg m-' and arain the dose-limiting toxicity was myalcia. Of 12
patients treated. there were three responses: two minor responses in
patients with low-grade lvmphoma and a partial response in a
patient heavily pre treated for ovarian carcinoma.
In our prexvious phase I study. 35 patients were treated wxith
brvostatin. Initially. the druo was dissolx-ed in ethanol and subse-
quently. in order to reduce the incidence of phlebitis. with PET
diluent. Bryostatin was infused oxer 1 h on days 1. 8 and 15 of a
13371338 DJ Propper etal
Table 1 Patient characteristcs
Parametr
Total number treated
Median age - years (range)
MernWomen
ECOG performance score
0
1
2
3
4
Stage of disease
Ill
IV
Sites of disease
Cutaneous only
Cutaneous + distant LN
Cutaneous + soft tissue
Liver
Liver + cutaneous
Liver + cutaneous + LN
Liver + lung
Liver + lung + LN
Liver + lung + cutaneous + LN
Lung
Lung + Bone
Lung + LN
Lung + cutaneous + LN
No. of patients
16
57 (35-76)
8: 8
6
9
1
0
15
2
1
2
12
LN. lymph node.
28-day cycle. The MTD u-as 25 jgc m' (Philip et al. 1993). The
dose-limiting toxicitvxwas also myalgia. There were two objective
responses. both in patients wxith metastatic melanoma: one had a
partial response in lung metastasis and the other a partial response
in skin metastases.
Immunological mechanisms are implicated in melanoma regres-
sion. In viexx of the responses observed in two patients with
melanoma in our phase I trial (Philip et al. 1993) and the known
immunostimulatorx properties ofbryostatin. we undertook a phase
II study of the effect of bryostatin 25 jgc m-' given over 1 h on
days 1. 8 and 15 of a 28-day cycle in patients x-ith metastatic
malignant melanoma.
PATIENTS AND METHODS
Eligibility criteria
Eligibilitv criteria for entrv included: histologically or cytologi-
cally proven metastatic malignant melanoma w-ith objective
exidence of progressive disease. Eastern Cooperative Oncology
Group (ECOG) performance status of0-2. white cell count greater
than 3.0 x 10 1-'. platelet count greater than 100 x 109 L-'. normal
renal and hepatic function. negative histor- of cardiac disease.
absence of active infection. life expectancy of at least 3 months.
presence of measurable or evaluable disease. and informed
consent. Patients had not receixed radiotherapy or chemotherapy
in the 4 weeks (6 weeks for nitrosoureas or mitomycin C) before
commencing, the study. The study was approved by the Central
Oxford Research Ethical Committee (COREC). and conducted
Table 2 Number of courses of bryostatin received. Median number of
courses: 3.5 (range 1-6)
Course No. of patients Reason off study (no. patients)
1 1 Myalgia (1)
2 3 PD (3)
3 4 PD (4)
4 3 PD (3)
5 3 PD (3)
6 2 PD (1)
Myalgia (1)
Response No. of patents
Complete response 0
Partial response 0
Stable disease 1
Progressive disease 14
Not evaluable 1
according to the declaration of Helsinki. The use ofbr ostatin had
UK Medicines Control Agency approval.
Drug administration
Brxostatin (US National Cancer Institute. Arizona State
Universitv/Cancer Research Institute. USA) was stored at 2-8 C
in vials containing 100 jg> of lvophilized pow-der. For administra-
tion. it was dissolx ed at a concentration of 10jgc ml-' in poly-
ethvlene glvcol. ethanol. and Txxeen 80 (PET. 60/30/10. v/x).
Powdered brvostatin was reconstituted with 1 ml ofPET diluent to
cive a concentration of 100 gcr ml-' which was further diluted at
least 1:20 with 0.9% saline to a final concentration of 5 jg ml-'.
All patients received 25 jgc m- given over 1 h on days 1. 8 and 15
of a 28-dav cycle. Polypropylene plastic syringes and 106.7 cm
Polyfin extension sets (MiniMed Technologies. CA. USA) were
employed in the preparation and administration of brvostatin to
avoid its absorbence onto plastic surfaces. The tubing of the drur
infusion svstem was primed with brvostatin solution at a concen-
tration similar to that administered to the patient in order to maxi-
mize the accuracy of the administered dose. Brvostatin solution
was administered as a controlled ix. infusion through a peripheral
venous line using a syringre pump.
Assessment of toxicity
Baseline investigations included full blood count Aith a differential
white cell count. serum biochemistry. urinalvsis. chest radiograph
and electrocardiogram. Patients were reviewed by a physician
weekly. and new signs and symptoms and performance status
(ECOG) were documented. At each visit, a full blood count with a
differential white cell count. serum biochemistrx and urinalssis
were performed. Additional tests were performed as appropriate.
World Health Organization (WHO) toxicity criteria were used
to grade the toxicity of bryostatin except for mvalgia. w-hich was
graded according to the follow'ing scale: grade 0- no pain: grade 1
- mild short-lived pain not requiring analgesics: grade 2 moder-
ately sexvere pain but patients remained ambulators with irreaular
analgesic intake: grade 3 - moderate to sexvere pain which signifi-
cantlv affected ambulation and required regular analgesia (non-
opiate): andgrade 4 -verv severe incapacitating pain necessitatine
constant bed rest and regular opiates.
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Table 3 Toxicities associated with bryostatin treatment
WHO grade 0 1 2 3 4 Total
Myalgia 2 0 8 6 0 16
Phlebitis 11 1 4 0 0 16
Headache 10 5 1 0 0 16
Fatigue 6 5 3 0 0 16
Nausea and vomiting 11 4 0 1 0 16
Diarrhoea 11 5 0 0 0 16
Maximal grade tox cities shown.
Table 4 Details of bryostatin-associated myalgia showing grade of myalgia
during each course
Course no.
Paffentno. 1 2 3 4 5 6
1 0 1 2 2 3 3
2 1 2 2 2
3 0 2 2 2 3
4 0 0
5 0 2 1
6 1 2 3 3
7 0 2 2 2 3
8 0 2 2
9 1 1 2 1 2 1
10 0 2 2
11 0 0 0 0
12 3
13 2 2 2
14 0 2 0 0 2
15 0 2
16 1 3
Assessment of tumour response
Ev-aluable and measurable disease sites w-ere assessed before
entering the study by phy sical examination. plain radiography and
computerized tomography where appropriate. and repeated evenr
t-wo cycles. Physical examination was repeated weekly and
imaging investigations for the purposes of tumour measurement
were repeated after two cycles of treatment or at the time of
suspected disease progression.
Standard W'HO criteria for objectix e response assessment vvere
employed. Partial response was defined as a 50%7 or greater reduc-
tion in the sum of the products of the largest perpendicular dia-
meters of all measurable disease sites. Progressive disease wxas
indicated by a greater than 25% increase in the size of at least one
measurable lesion. or the appearance of a new lesion. Stable
disease was defined as an increase in disease measurements ofless
than 25% or a decrease by less than 50%. Patients with progressixe
disease were withdrawn from the study.
Patients
Sixteen patients (eight men. eicht w-omen: age range 35-76 years)
were recruited to the study. All patients had prexiously receixed
chemotherapy w-ith dacarbazine (DTIC) given as I g m- oxver I h
once even 3 w-eeks. and four had in addition receixed radio-
therapy. One ofthe patients Aas treated Aith DTIC in combination
u-ith BCNU (carmustine). cisplatin and tamoxifen afterdexeloping
progressix e disease on DTIC. This regimen is further detailed else-
where (Del Prete et al. 1984). In 14 patients. there had been disease
progression in response to chemotherapy. one patient achieved
stable disease. and one v.-as not exaluable because the
chemotherapy x-as given in the adjuxvant setting. Their characteris-
tics are show-n in Table 1.
STATISTICS
To ensure a low probability of erroneously rejecting, a treatment
that is active in 20% of patients. at least 14 patients were treated.
according to previously described principles (Gehan. 1961).
RESULTS
Of 16 patients treated. 15 w-ere ex-aluable for disease response
(Table 2). The remaininc patient >-as withdrawn from the studv
after one treatment course (1 week) because of sexere (grade 3
mvalgia.
The mean number of weeklv treatment courses gixen was 3.6
(median 3.5. range 1-6: Table 2). Of the 15 exaluable patients. 14
stopped treatment because of progressix e disease. The remaining
patient. who had pulmonary metastases. attained stable disease for
9 months after treatment and w as ithdrawn from treatment
because of worsenina (arade 3) myalaia after six courses. The
median survixal from commencinc brvostatin xas 134 days (95%7-
CI = 67-308).
The toxicities associated wxith treatment are shown in Tables 3 and
4. Eight patients developed grade 2 myralgia and six had grade 3
myralaia. In aeneral. the myalgia orsened ith each course ofbryo-
statin (Table 4). Studies in xixo haxe suaaested that this mvalgia
may be caused by impairment of oxidative metabolism. possibly as
a result of x-asoconstriction. In an attempt to reverse xvasoconstric-
tion. six patients were treated wxith nifedipine but this was ineffec-
tixe. as prexviously reported (Thompson et al. 1996). Apart from
my algia. the incidence ofsexere toxicit- w as lowx. Of note. there w as
no significant biochemical or haematolocical toxicirx.
DISCUSSION
In this studx of 15 exaluable patients treated xxith brvostatin. only
one patient. whose disease stabilized. obtained significant benefit
from the drug. Apart from this patient. the remainder were xith-
drax n from treatment because ofdisease progression and. in sexven
patients. this occurred ithin 1 month of starting bnostatin.
Hence. single-acent bry-ostatin. gixven by this formulation at a dose
of 25 go m-' administered oxver I h weekly for 3 wxeeks of a 4-
wxeek cycle. is not an effectixe therapy for metastatic melanoma in
patients prexiously treated ith chemotherapy.
In our prexious phase I study of bryostatin. disease responses
wxere observed in two patients ith melanoma (Phihip et al. 1993).
and there are theoretical reasons hy bn ostatin might be
construed as a potentially effectixe therapy for melanoma. It has
anti-tumour effects in murine models of melanoma and on
melanoma cell lines (Schuchter et al. 1991: Szallasi et al. 1996).
Immunolocgical mechanisms are implicated in the regression of
melanoma. and br ostatin stimulates cvtokine release and
augrments specific anti-tumour immunitx (Mohr et al. 1987: Tuttle
et al. 1992: Steube and Drexler. 1995).
There are sexeral reasons w-hich might explain the drug's lack of
clinical effect in this phase H study. Animal data suggest that the
British Joumal ofCancer (1998) 78(10). 1337-1341 0 Cancer Research Campaign 19981340 DJ Propper etal
half-life of bryostatin is short (Berkow- et al. 1993: Zhang et al.
1996). and its anti-tumour effects are potentiated w-hen given over
a prolonged penrod (Homung et al. 1992). Indeed. in a previous
phase I trial (Jayson et al. 1995): when the druc was given as a
24-h infusion. partial tumour responses were observed using the
same drug dose as aiven in the current study. but. when the same
or higher doses were Diven over 1 h. no tumour responses were
observed (Prendiville et al. 1993). In this latter studv. however. the
drug was administered on a 2 weekly. rather than a wveekly
schedule. Nevertheless. we have observed partial disease
responses in tWo patients w-ith melanoma who were treated with
brvostatin bv 1 h bolus infusion at the same dose and by the same
weekly schedule as used in the current study (Philip et al. 1993).
Expression of PKC isotypes in tumours varies (Guillem et al.
1987: O'Brian and Ward. 1989: Barr et al. 1991: Couldwell et al.
1991). and not all are equally down-regulated by bryostatin
(Szallasi et al. 1994b). PKC isoenzvmes are involved in both
oncogene and tumour-suppressor gene acti-ation and could have
opposing effects on tumour growth. dependent on tumour type.
Hence the clinical effects ofbrvostatin are likely to be complex.
Toxicity in this study. apart from mvalaia. was low. Phlebitis. a
prevalent feature w-hen the drug w-as dissolved in ethanol (Philip et
al. 1993). wAas minimized by the PET diluent. Myalgia was a
prominent feature in the patients studied here. The myalgia
occurred within 2-3 days of drug administration and lasted 3-5
days. As in previous studies. it worsened incrementallyA with
further courses of brvostatin. Its aetiolo5v is unknown. and
appears to be a direct drug effect on muscle (Hickman et al. 1995:
Thompson et al. 1996). Other studies have shown that the myalgia
is not reversed by nifedipine. a drug that does reverse brvostatin-
induced vasoconstriction (Thompson et al. 1996 . Corticosteroids.
non-steroidal anti-inflammatory drugs and a variety ofanalgresics.
including morphine. have not proven effective in the treatment of
this toxicitv. Further assessment of the aetiologv of the myalaia
and development of methods of reversing it could allow higher
doses than used here to be administered which would perhaps
attain therapeutic levels.
Some brvostatin analogues have been shown. in murine models.
to have equal anti-tumour effects but less toxicity than brvostatin 1
(Kraft et al. 1996). Furthermore. there is evidence that the toxicity.
but not the anti-tumour effects of some bryostatin analogues. is
mediated by direct interaction with PKC (Szallasi et al. 1996).
Hence. clinical testing ofbrvostatin analogues may be of value.
All patients in this study had previously received chemotherapy.
and four had received radiotherapy. Therefore. it is likely that
there was significant suppression in lymphocyte function. which
could have reduced the possibility ofbrvostatin actinc by immune-
mediated mechanisms. Further studies are indicated in chemo-
therapy naive patients.
In vitro. bryostatin potentiates cvtotoxic agent activity (Basu
and Lazo. 1992: Mohammad et al. 1995). Also. although there is
conflicting evidence. bryostatin may act as a multidruc, resistance
(MDR) modulator (Kamanda et al. 1994: Scala et al. 1995). The
lack of significant myelotoxcity in this and previous phase I
studies indicates that the drugr could be nriven in combination with
cytotoxic agrents.
In peripheral blood lymphocytes (PBLs) obtained from patients
receiving brvostatin. LAK cell generation and proliferation were
enhanced following in vitro stimulation with interleukin 2 (IL-2)
w-hen comparedAwith PBLs obtained fromhealthy control subjects.
In conjunction w-ith 1L-2. brxrostatin up-regulated IL-' receptor
expression and augmented cvtotoxic T-lymphocyte (CTL)
numbers in vitro (Scheid et al. 1994). Hence. brvostatin and
cytokine therapy may be synergistic.
The findincs ofthis study showv that brvostatin is not effective as
a single agent in metastatic malicnant melanoma. Experimental
evidence suggests that it may warrant further study in combination
with cvtotoxic or biological agents.
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